Innate Pharma Stock Market Outlook
| IPHA Stock | USD 1.76 0.00 0.00% |
About 62% of Innate Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Innate Pharma suggests that many traders are alarmed. The current market sentiment, together with Innate Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Innate Pharma stock news signals to limit their universe of possible portfolio assets.
Comfort Level 38
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Innate Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Innate Pharma.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Innate Pharma is 'Strong Sell'. Macroaxis provides Innate Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IPHA positions.
Execute Innate Pharma Advice
The Innate recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Innate Pharma. Macroaxis does not own or have any residual interests in Innate Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Innate Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Innate Pharma has a Mean Deviation of 2.02, Standard Deviation of 2.68 and Variance of 7.16We provide advice to complement the regular expert consensus on Innate Pharma. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Innate Pharma is not overpriced, please check out all Innate Pharma fundamentals, including its cash and equivalents, cash flow from operations, and the relationship between the gross profit and debt to equity . Please also validate Innate Pharma number of shares shorted to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Innate Pharma Trading Alerts and Improvement Suggestions
| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| The company reported the previous year's revenue of 12.62 M. Net Loss for the year was (49.47 M) with loss before overhead, payroll, taxes, and interest of (30.79 M). | |
| Innate Pharma currently holds about 123.35 M in cash with (6.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. | |
| Innate Pharma has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: Will Innate Pharma S.A. Depositary Receipt stock maintain growth story - Portfolio Update Report Daily Entry Point Alerts - mfd.ru |
Innate Pharma Returns Distribution Density
The distribution of Innate Pharma's historical returns is an attempt to chart the uncertainty of Innate Pharma's future price movements. The chart of the probability distribution of Innate Pharma daily returns describes the distribution of returns around its average expected value. We use Innate Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Innate Pharma returns is essential to provide solid investment analysis for Innate Pharma.
| Mean Return | -0.39 | Value At Risk | -4.49 | Potential Upside | 3.41 | Standard Deviation | 2.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Innate Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Innate Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 51.2 K | Steward Partners Investment Advisory, Llc | 2025-03-31 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 26.6 K | Millennium Management Llc | 2025-06-30 | 11.7 K | Ubs Group Ag | 2025-06-30 | 6 K | Gamma Investing Llc | 2025-06-30 | 3.5 K | Rhumbline Advisers | 2025-06-30 | 470 | Barclays Plc | 2025-06-30 | 307 | Optiver Holding B.v. | 2025-06-30 | 101 | Principal Securities Inc | 2025-06-30 | 45.0 | Tower Research Capital Llc | 2025-06-30 | 0.0 |
Innate Pharma Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | (33.0M) | (19.5M) | (13.6M) | (4.2M) | (3.8M) | (3.6M) | |
| Free Cash Flow | (59.8M) | (20.3M) | (34.9M) | (7.3M) | (6.6M) | (6.9M) | |
| Depreciation | 4.6M | 45.4M | 5.1M | 2.0M | 2.3M | 2.2M | |
| Other Non Cash Items | (1.3M) | 1.8M | (2.2M) | (2.5M) | (2.3M) | (2.2M) | |
| Capital Expenditures | 1.3M | 1.1M | 2.4M | 391K | 449.7K | 427.2K | |
| Net Income | (52.8M) | (58.1M) | (7.6M) | (49.5M) | (44.5M) | (42.3M) | |
| End Period Cash Flow | 103.8M | 84.2M | 70.6M | 66.4M | 76.4M | 83.9M | |
| Investments | (917K) | 1.9M | 20.6M | 9.2M | 10.6M | 11.1M | |
| Net Borrowings | 26.6M | (2.0M) | (2.4M) | (8.9M) | (8.0M) | (7.6M) | |
| Change To Netincome | (1.1M) | 4.6M | (360K) | 6.0M | 7.0M | 7.3M |
Innate Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Innate Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Innate Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Innate stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.38 | |
β | Beta against Dow Jones | -0.26 | |
σ | Overall volatility | 2.19 | |
Ir | Information ratio | -0.17 |
Innate Pharma Volatility Alert
Innate Pharma exhibits very low volatility with skewness of -0.79 and kurtosis of 1.96. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Innate Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Innate Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Innate Pharma Fundamentals Vs Peers
Comparing Innate Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Innate Pharma's direct or indirect competition across all of the common fundamentals between Innate Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Innate Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Innate Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Innate Pharma to competition |
| Fundamentals | Innate Pharma | Peer Average |
| Return On Equity | -2.71 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Operating Margin | (5.23) % | (5.51) % |
| Current Valuation | 124.12 M | 16.62 B |
| Shares Outstanding | 93.72 M | 571.82 M |
| Shares Owned By Insiders | 1.69 % | 10.09 % |
| Shares Owned By Institutions | 0.24 % | 39.21 % |
| Number Of Shares Shorted | 210.41 K | 4.71 M |
| Price To Book | 26.70 X | 9.51 X |
| Price To Sales | 12.91 X | 11.42 X |
| Revenue | 12.62 M | 9.43 B |
| Gross Profit | (30.79 M) | 27.38 B |
| EBITDA | (46.91 M) | 3.9 B |
| Net Income | (49.47 M) | 570.98 M |
| Cash And Equivalents | 123.35 M | 2.7 B |
| Cash Per Share | 1.54 X | 5.01 X |
| Total Debt | 31 M | 5.32 B |
| Debt To Equity | 0.37 % | 48.70 % |
| Current Ratio | 2.34 X | 2.16 X |
| Book Value Per Share | 0.07 X | 1.93 K |
| Cash Flow From Operations | (6.9 M) | 971.22 M |
| Short Ratio | 10.17 X | 4.00 X |
| Earnings Per Share | (0.65) X | 3.12 X |
| Target Price | 5.75 | |
| Number Of Employees | 174 | 18.84 K |
| Beta | 0.57 | -0.15 |
| Market Capitalization | 163.08 M | 19.03 B |
| Total Asset | 111.06 M | 29.47 B |
| Retained Earnings | (386.36 M) | 9.33 B |
| Working Capital | 52.76 M | 1.48 B |
| Net Asset | 111.06 M |
Innate Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Innate . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0806 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.79 | |||
| Day Typical Price | 1.78 | |||
| Market Facilitation Index | 0.15 | |||
| Price Action Indicator | (0.03) |
About Innate Pharma Buy or Sell Advice
When is the right time to buy or sell Innate Pharma? Buying financial instruments such as Innate Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Innate Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Innate Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. Market participants price Innate higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innate Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Innate Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.